Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced equity awards granted on August 30, 2024 under its 2024 Employment Commencement Incentive Plan. Approved by the Compensation Committee of the Board of Directors, these awards serve as a material inducement for 20 new employees hired in August 2024. The awards include a total of 9,290 restricted stock units (RSUs), which will vest annually over four years, contingent on continued employment. Employees did not receive options to purchase shares of Sarepta's common stock. Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs) and has over 40 programs in development.
Sarepta Therapeutics (NASDAQ:SRPT), un leader nella medicina genetica di precisione per malattie rare, ha annunciato i riconoscimenti azionari concessi il 30 agosto 2024 nell'ambito del suo Piano Incentivi per l'Inizio dell'Occupazione 2024. Approvati dal Comitato per le Compensazioni del Consiglio di Amministrazione, questi riconoscimenti fungono da incentivo determinante per 20 nuovi dipendenti assunti ad agosto 2024. I riconoscimenti comprendono un totale di 9.290 unità di azioni riservate (RSU), che matureranno annualmente nell'arco di quattro anni, a condizione di un'occupazione continuativa. I dipendenti non hanno ricevuto opzioni per l'acquisto di azioni comuni di Sarepta. Sarepta si concentra sullo sviluppo di trattamenti per la distrofia muscolare di Duchenne (DMD) e per le distrofie muscolari a cintura (LGMD) e ha oltre 40 programmi in sviluppo.
Sarepta Therapeutics (NASDAQ:SRPT), un líder en medicina genética de precisión para enfermedades raras, anunció la concesión de premios en acciones el 30 de agosto de 2024 bajo su Plan de Incentivos para el Comienzo del Empleo 2024. Aprobados por el Comité de Compensaciones de la Junta Directiva, estos premios sirven como un incentivo material para 20 nuevos empleados contratados en agosto de 2024. Los premios incluyen un total de 9,290 unidades de acciones restringidas (RSUs), que se otorgarán anualmente durante cuatro años, dependiendo de la continuidad del empleo. Los empleados no recibieron opciones para comprar acciones ordinarias de Sarepta. Sarepta se enfoca en desarrollar tratamientos para la distrofia muscular de Duchenne (DMD) y las distrofias musculares de cintura (LGMD), y tiene más de 40 programas en desarrollo.
사레프타 치료제(Sarepta Therapeutics) (NASDAQ:SRPT)는 희귀 질환을 위한 정밀 유전 의학의 선두주자로서, 2024년 8월 30일에 2024년 고용 시작 인센티브 계획에 따라 주식 보상을 발표했습니다. 보상위원회에서 승인된 이 상은 2024년 8월에 채용된 20명의 신입 직원에게 실질적인 유인으로 작용합니다. 이 보상에는 총 9,290개의 제한 주식 단위(RSU)가 포함되며, 이는 고용이 지속되는 조건 하에 4년에 걸쳐 매년 지급됩니다. 직원들은 사레프타의 보통주 구매 옵션을 받지 않았습니다. 사레프타는 두센 근이영양증(DMD) 및 사지-허리 근이영양증(LGMD)을 치료하기 위한 개발에 집중하고 있으며, 40개 이상의 프로그램이 개발 중입니다.
Sarepta Therapeutics (NASDAQ:SRPT), un leader dans la médecine génétique de précision pour les maladies rares, a annoncé des attributions d'actions le 30 août 2024 dans le cadre de son Plan d'Incitation à l'Emploi 2024. Approuvées par le Comité de Rémunération du Conseil d'Administration, ces attributions servent d'incitation substantielle pour 20 nouveaux employés recrutés en août 2024. Les attributions incluent un total de 9 290 unités d'actions restreintes (RSU), qui seront acquises annuellement sur quatre ans, sous réserve d'un emploi continu. Les employés n'ont pas reçu d'options pour acheter des actions ordinaires de Sarepta. Sarepta se concentre sur le développement de traitements pour la dystrophie musculaire de Duchenne (DMD) et les dystrophies musculaires ceinturales (LGMD), et dispose de plus de 40 programmes en développement.
Sarepta Therapeutics (NASDAQ:SRPT), ein führendes Unternehmen in der präzisen Gentherapie für seltene Krankheiten, gab die Gewährung von Eigenkapitalprämien am 30. August 2024 im Rahmen seines Anreizplans für den Beschäftigungsbeginn 2024 bekannt. Die vom Entschädigungsausschuss des Aufsichtsrats genehmigten Prämien stellen einen wesentlichen Anreiz für 20 neue Mitarbeiter dar, die im August 2024 eingestellt wurden. Die Prämien umfassen insgesamt 9.290 eingeschränkte Aktieneinheiten (RSUs), die über einen Zeitraum von vier Jahren jährlich fällig werden, abhängig von der fortgesetzten Beschäftigung. Den Mitarbeitern wurden keine Optionen zum Kauf von Stammaktien von Sarepta gewährt. Sarepta konzentriert sich auf die Entwicklung von Behandlungen für die Duchenne-Muskeldystrophie (DMD) und die Gürteldystrophien (LGMD) und hat über 40 Programme in der Entwicklung.
- Granting of 9,290 RSUs to 20 new employees could help attract and retain top talent.
- Vesting schedule of RSUs encourages long-term employment with the company.
- No stock options were granted to employees, potentially limiting their equity compensation.
The employees received in the aggregate 9,290 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240830790712/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
What did Sarepta Therapeutics announce on August 30, 2024?
How many RSUs did Sarepta award to new employees in August 2024?
What is the vesting schedule for the RSUs granted by Sarepta Therapeutics?
Did Sarepta Therapeutics grant stock options to new employees in August 2024?
Under which rule were the equity awards approved by Sarepta Therapeutics?
